These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 14569639

  • 1. Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults age > or = 65.
    Whitney CG.
    Geriatrics; 2003 Oct; 58(10):20-2, 25. PubMed ID: 14569639
    [Abstract] [Full Text] [Related]

  • 2. Rethinking recommendations for use of pneumococcal vaccines in adults.
    Whitney CG, Schaffner W, Butler JC.
    Clin Infect Dis; 2001 Sep 01; 33(5):662-75. PubMed ID: 11486289
    [Abstract] [Full Text] [Related]

  • 3. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
    Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices.
    MMWR Morb Mortal Wkly Rep; 2010 Sep 03; 59(34):1102-6. PubMed ID: 20814406
    [Abstract] [Full Text] [Related]

  • 4. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Advisory Committee on Immunization Practices.
    MMWR Recomm Rep; 2000 Oct 06; 49(RR-9):1-35. PubMed ID: 11055835
    [Abstract] [Full Text] [Related]

  • 5. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2012 Oct 12; 61(40):816-9. PubMed ID: 23051612
    [Abstract] [Full Text] [Related]

  • 6. Pneumococcal polysaccharide vaccine. Recommendation of the Immunization Practices Advisory Committee.
    Ann Intern Med; 1982 Feb 12; 96(2):203-5. PubMed ID: 6277218
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
    Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW, Vaccine Safety Datalink.
    N Engl J Med; 2003 May 01; 348(18):1747-55. PubMed ID: 12724480
    [Abstract] [Full Text] [Related]

  • 8. Higher pneumococcal disease vaccination rates needed to protect more at-risk US adults.
    Rehm SJ, Farley MM, File TM, Hall WJ, Hopkins R, Levine OS, Nichol KL, Nuorti P, Zimmerman RK, Schaffner W.
    Postgrad Med; 2009 Nov 01; 121(6):101-5. PubMed ID: 19940420
    [Abstract] [Full Text] [Related]

  • 9. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention.
    Lynch JP, Zhanel GG.
    Semin Respir Crit Care Med; 2009 Apr 01; 30(2):189-209. PubMed ID: 19296419
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003.
    Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, Long C, Gershman K, Pilishvili T, Roberson A, Zell ER, Whitney CG, Bennett NM, Active Bacterial Core Surveillance Program of the Emerging Infections Program Network.
    Clin Infect Dis; 2006 Jul 15; 43(2):141-50. PubMed ID: 16779739
    [Abstract] [Full Text] [Related]

  • 12. Education does pay off: pneumococcal vaccine screening and administration in hospitalized adult patients with pneumonia.
    Kruspe R, Lillis R, Daberkow DW, Blais CM, Wilbright W, Gupta S, Gould CA, Sun T, Martinez JA, deBoisblanc B, Ladabaum U, Sanders CV, Lopez FA.
    J La State Med Soc; 2003 Jul 15; 155(6):325-31. PubMed ID: 14750752
    [Abstract] [Full Text] [Related]

  • 13. Pneumococcal vaccine in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness.
    Simberkoff MS.
    Semin Respir Infect; 1993 Dec 15; 8(4):294-9. PubMed ID: 7938926
    [Abstract] [Full Text] [Related]

  • 14. Time for changes in pneumococcal vaccination of adults?
    Overman MC.
    J Am Osteopath Assoc; 2011 Oct 15; 111(10 Suppl 6):S19-22. PubMed ID: 22086890
    [Abstract] [Full Text] [Related]

  • 15. Increasing pneumococcal vaccination rates among patients of a National Health-Care Alliance--United States, 1993.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 1995 Oct 13; 44(40):741-4. PubMed ID: 7565554
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine--United States, 1997-2006.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2009 Jan 16; 58(1):1-4. PubMed ID: 19145219
    [Abstract] [Full Text] [Related]

  • 19. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2012 Jun 01; 61(21):394-5. PubMed ID: 22647745
    [Abstract] [Full Text] [Related]

  • 20. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness.
    Fedson DS.
    Semin Respir Infect; 1993 Dec 01; 8(4):285-93. PubMed ID: 7938925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.